|Nasdaq:||GOOG NFLX AMZN BIIB IBB TSLA ILMN ALXN AMGN COST FFIV TRIP SBAC PCYC WDC VRTX AAPL SNDK BEAV|
|Nyse:||V ACT IVV IBM MCK LNKD GS SPG AGN LMT FDX CMI TWC XEC WHR MMM APD CVX TMO|
|New Highs:||MCK PSA LMT NOC GD SBAC UHS LEA MCO R DECK WLK ADP CAM LPNT UA NTRS MAR CHRW HCA|
Spectrum Pharmaceuticals, Inc., a biotechnology company, develops and commercializes oncology and hematology drug products. The companys commercialized drug products include FUSILEV for the treatment of patients with metastatic colorectal cancer, rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma; ZEVALIN injection for intravenous use as a prescription medication; and MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation of the anticancer drug vincristine for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. It also develops BELEODAQ for the treatment of various hematological and solid tumors; Captisol-enabled MELPHALAN, an intravenous formulation of MELPHALAN for clinicians and patients in the multiple myeloma transplant setting; APAZIQUONE to treat non-muscle invasive bladder cancer; and SPI-2012 for the treatment of chemotherapy-induced neutropenia. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe and Japan. It has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan; collaboration agreement with Nippon Kayaku Co., Ltd.; licensing and collaboration agreement with TopoTarget A/S; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.